Skip to main content
Cansino Biologics Inc. logo

Cansino Biologics Inc. — Investor Relations & Filings

Ticker · 688185 ISIN · CNE100004BM0 LEI · 254900SPBQ0ZVM8QC931 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 753 across all filing types
Latest filing 2026-05-19 Proxy Solicitation & In…
Country CN China
Listing Shanghai Stock Exchange 688185

About Cansino Biologics Inc.

https://www.cansinotech.com/

CanSino Biologics Inc. is a biopharmaceutical company dedicated to the development, manufacturing, and commercialization of innovative vaccine products. The company utilizes four core technology platforms: adenovirus-based viral vector technology, protein structure design and recombinant technology, conjugation technology, and formulation technology. Its product portfolio includes Convidecia, a recombinant COVID-19 vaccine (Ad5-nCoV) available in both injectable and inhaled forms, and Menhyke and Menace, which are meningococcal conjugate vaccines. CanSino Biologics also advances a diverse pipeline targeting infectious diseases such as Ebola virus disease, pneumonia, and tuberculosis. By leveraging its integrated R&D and large-scale manufacturing capabilities, the company aims to provide high-quality, accessible vaccines to address global public health needs and emerging infectious disease threats.

Recent filings

Filing Released Lang Actions
关于2025年年度股东会变更会议地址的公告
Proxy Solicitation & Information Statement Classification · 72% confidence The document is a shareholder meeting announcement detailing the change of venue for the 2025 Annual General Meeting, including meeting date/time, agenda proposals, voting procedures, and a proxy authorization form. It serves to provide information to shareholders and solicit their votes via proxy, which matches the definition of Proxy Solicitation & Information Statement (PSI).
2026-05-19 Chinese
2025年年度股东会会议资料
AGM Information Classification · 95% confidence The document is the full set of materials for the company’s 2025 Annual General Meeting (AGM), including meeting agenda, proposals, procedural rules, and reports to be presented at the shareholders’ meeting. This matches the definition for AGM Information (materials shared during an AGM).
2026-05-19 Chinese
自愿披露关于吸附无细胞百（五组分）白破联合疫苗（6岁及以上人群用）正式纳入优先审评品种的公告
Regulatory Filings Classification · 75% confidence The document is a voluntary corporate announcement in Chinese about a vaccine product being included in a priority review list by the National Medical Products Administration. It contains no financial statements, share changes, AGM materials, or executive appointments. It is an operational update/press announcement filed with the exchange, falling into the generic regulatory announcement category. Therefore, it should be classified as Regulatory Filings (RNS).
2026-05-11 Chinese
2025年度会计师事务所履职情况评估报告
Audit Report / Information Classification · 95% confidence The document is titled as an evaluation report on the performance of the accounting firms (Deloitte Huayong and Deloitte Hong Kong) for the year 2025. It details the qualifications, independence, quality management, audit plans, and resources related to the audit firms engaged by the company. The content focuses on the audit firms' compliance, quality control, and audit execution rather than presenting the company's financial statements or results. It is a standalone audit-related report assessing the auditor's performance and quality management, not the full annual report or audit report itself. The document length is about 4731 characters, which is substantial and contains detailed evaluation information, not just an announcement or certification. Therefore, it fits best under the category of Audit Report / Information (AR). FY 2025
2026-03-30 Chinese
独立董事2025年度述职报告（张耀樑）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director 2025 Annual Work Report" for 康希诺生物股份公司 (CanSino Biologics Inc.). It is a detailed report by an independent director summarizing their duties, attendance, communications, and evaluations over the 2025 fiscal year. The content focuses on governance, board activities, audit committee interactions, and compliance with laws and company bylaws. It does not contain financial statements or earnings data but is a formal report on the independent director's annual duties and observations. This type of document fits best under Board/Management Information (MANG), as it relates to board member activities and governance reporting rather than financial results or audit reports. The document length is 4361 characters, which is sufficient for a detailed report but not a full annual report or audit report. Therefore, the classification is MANG with high confidence.
2026-03-30 Chinese
2025年环境、社会及管治（ESG）暨可持续发展报告
Environmental & Social Information Classification · 95% confidence The document is a comprehensive Environmental, Social and Governance (ESG) sustainability report for Consern Biotech covering ESG management system, climate change response, social responsibility, governance structure, materiality assessment, stakeholder communication, and detailed ESG data tables. It is not an announcement or proxy, nor a financial statement, but a standalone ESG report. This matches the Environmental & Social Information category.
2026-03-30 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.